Literature DB >> 11519849

Genetic basis of pituitary adenoma invasiveness: a review.

A Suhardja1, K Kovacs, J Rutka.   

Abstract

Compatible with contemporary paradigms of the role of genetic aberrations in the progression of human tumors, the growth of pituitary tumors into a state of invasiveness appears to be due to genetic alterations. Amplification of H-ras and c-myc oncogenes and mutations of p53, nm23 and Rb genes have been identified disproportionately more in aggressive tumors and, in the case of Rb gene, in pituitary carcinomas, providing evidence that amplification of these oncogenes (H-ras and c-myc) and inactivation of tumor suppressor genes (p53, nm23 and Rb) seem to be at least one mechanism by which pituitary tumors progress. The current level of management of invasive pituitary adenomas should become more comprehensive as the advances in our understanding of genetic basis of pituitary adenoma invasiveness becomes translated into development of novel chemotherapy or gene transfer technique.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11519849     DOI: 10.1023/a:1010655419332

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  108 in total

1.  Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors.

Authors:  M Woloschak; A Yu; J Xiao; K D Post
Journal:  Int J Cancer       Date:  1996-07-03       Impact factor: 7.396

2.  Prolactin stimulates transcription of growth-related genes in Nb2 T lymphoma cells.

Authors:  L Y Yu-Lee
Journal:  Mol Cell Endocrinol       Date:  1990-01-02       Impact factor: 4.102

Review 3.  Current concepts in neuro-oncology: the cell cycle--a review.

Authors:  P B Dirks; J T Rutka
Journal:  Neurosurgery       Date:  1997-05       Impact factor: 4.654

4.  Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus.

Authors:  J Jayaraman; C Prives
Journal:  Cell       Date:  1995-06-30       Impact factor: 41.582

5.  DNA-binding domain of human c-Myc produced in Escherichia coli.

Authors:  C V Dang; H van Dam; M Buckmire; W M Lee
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

6.  Human pituitary tumours: studies on genes expression.

Authors:  A C Cherñavsky; A Chervin; M Vitale; A Basso; J A Burdman
Journal:  Neurol Res       Date:  1993-02       Impact factor: 2.448

7.  Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product.

Authors:  A K Rustgi; N Dyson; R Bernards
Journal:  Nature       Date:  1991-08-08       Impact factor: 49.962

8.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

9.  High levels of nm23-H1 and nm23-H2 messenger RNA in human squamous-cell lung carcinoma are associated with poor differentiation and advanced tumor stages.

Authors:  M Engel; B Theisinger; T Seib; G Seitz; H Huwer; K D Zang; C Welter; S Dooley
Journal:  Int J Cancer       Date:  1993-09-30       Impact factor: 7.396

10.  Interaction of c-Myc with the pRb-related protein p107 results in inhibition of c-Myc-mediated transactivation.

Authors:  R L Beijersbergen; E M Hijmans; L Zhu; R Bernards
Journal:  EMBO J       Date:  1994-09-01       Impact factor: 11.598

View more
  10 in total

1.  Prolactin-producing pituitary adenoma associated with prolactin cell hyperplasia.

Authors:  Sergio Vidal; Eva Horvath; Luis V Syro; Humberto Uribe; Sandy Cohen; Kalman Kovacs
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

2.  Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells.

Authors:  S R Sangeetha; Nagendra Singh; John R Vender; Krishnan M Dhandapani
Journal:  Endocrine       Date:  2009-03-17       Impact factor: 3.633

3.  Genomic instability in pituitary adenomas.

Authors:  Janusz Szymas; Karsten Schluens; Wlodzimierz Liebert; Iver Petersen
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 4.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

Review 5.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

6.  Potential markers of disease behavior in acromegaly and gigantism.

Authors:  Laura C Hernández-Ramírez
Journal:  Expert Rev Endocrinol Metab       Date:  2020-05-06

Review 7.  Prognostic indicators in pituitary tumors.

Authors:  Agustinus Suhardja; Kalman Kovacs; Oded Greenberg; Bernd W Scheithauer; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 4.056

8.  mTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation.

Authors:  Sangeetha Sukumari-Ramesh; Nagendra Singh; Krishnan M Dhandapani; John R Vender
Journal:  Surg Neurol Int       Date:  2011-02-23

9.  Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland.

Authors:  Laura C Hernández-Ramírez; Rhodri M L Morgan; Sayka Barry; Fulvio D'Acquisto; Chrisostomos Prodromou; Márta Korbonits
Journal:  Oncotarget       Date:  2018-01-11

10.  Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.

Authors:  Christian P Miermeister; Stephan Petersenn; Michael Buchfelder; Rudolf Fahlbusch; Dieter K Lüdecke; Annett Hölsken; Markus Bergmann; Hans Ulrich Knappe; Volkmar H Hans; Jörg Flitsch; Wolfgang Saeger; Rolf Buslei
Journal:  Acta Neuropathol Commun       Date:  2015-08-19       Impact factor: 7.801

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.